Skip to content
Medical Health Aged Care

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Zenas BioPharma 3 mins read

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading on the Nasdaq Global Select Market on September 13, 2024 under the ticker symbol “ZBIO”. The offering is expected to close on September 16, 2024, subject to the satisfaction of customary closing conditions. In addition, Zenas has granted the underwriters a 30-day option to purchase up to an additional 1,985,294 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offering.

Registration statements relating to the shares being sold in the offering have been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on September 12, 2024. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; and from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, timing and size of the initial public offering and the commencement of trading on the Nasdaq Global Select Market. Each forward-looking statement is subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described or at all. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Zenas, including, without limitation, market conditions, failure of customary closing conditions and the factors discussed in the “Risk Factors” section of the prospectus that forms a part of the registration statement, in the form last filed with the SEC. These forward-looking statements speak only as of the date of this press release and Zenas undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com


More from this category

  • Agriculture Farming Rural, Medical Health Aged Care
  • 11/02/2025
  • 17:00
Council of Presidents of Medical Colleges

Medical Colleges Double Down on Training Specialists for Regional Australia

Australia's medical colleges are backing their commitment to regional healthcare with concrete action, launching an unprecedented expansion of specialist training in regional, rural, and remote areas. This expansion reflects a coordinated effort across all medical colleges to address the critical shortage of specialists outside major cities. "Our rural and regional communities deserve the same access to specialist care as our cities," said Associate Professor Sanjay Jeganathan, Chair of the Council of Presidents of Medical Colleges (CPMC). "We're seeing real results from our colleges' commitment to rural training." The Royal Australian College of General Practitioners has filled all rural training positions…

  • Government VIC, Medical Health Aged Care
  • 11/02/2025
  • 15:33
Foundation for Alcohol Research and Education

FARE supports Victorian Coroner’s calls for alcohol delivery reforms

The Foundation for Alcohol Research and Education (FARE) has supported Coroner Ingrid Giles’ call for reforms to the state’s alcohol laws today, including restrictions to the delivery of alcohol. Following the Inquest into the death of Victorian woman, Ms Kathleen Arnold, due to “alcohol toxicity in the context of chronic alcohol consumption,” the Coroner’s recommendations include: - prohibit home delivery of alcohol between 10pm and 10am. - require a minimum two-hour delay between order and dispatch of alcohol for home delivery. - develop a new Alcohol Action Plan or a program of work (including specific actions,timeframes, accountabilities, and public reporting…

  • Contains:
  • Medical Health Aged Care
  • 11/02/2025
  • 15:20
Royal Australian College of GPs

WA Liberals package a model for rebuilding GP access: RACGP

The Royal Australian College of GPs (RACGP) has praised today’s announcement of a package to increase Western Australians’ access to GPs and reduce hospital readmissions by the state opposition as parties in WA gear up for the 8 March election. The $140 million package includes $40,000 GP training incentive grants to grow WA’s specialist GP workforce, funding to give hospital-based junior doctors hands-on experience in accredited general practices, $60 million funding for patients to consult with a specialist GP following hospital discharge, and funding to upskill GPs in prescribing for ADHD. Several of these measures reflect solutions that have been…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.